However, when administered exogenously both intratumorally or intradermally alongside a Her2/neu DNA plasmid vaccine, CCL19 was able to elicit a Th1 anti-tumor response in a mouse model of Her2/neu positive breast cancer [62,63]. This evidence concerns the gene ERBB2 and neoplasm.